Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

Conspiracies might be fun to entertain. But the "big lie" tactic destroys your judgment and credibility. Find out why, and ...

We explain how aluminium went from a luxury metal to a world changing material. In the 1800s it was more expensive than gold. New refining methods dropped the price from $1.200 per kilo to just $1.

Before market open, Recursion divulged that its REC-4881 demonstrated notable efficacy in a phase 1b/2 trial. The drug, which treats a disorder called familial adenomatous polyposis (FAP) in which ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best NASDAQ stocks under $10 to buy. As of December 15, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has a ‘Hold’ or equivalent rating from ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

We tend to think of liking and wanting as the same thing. We want what (and who) we like—and vice versa. But what happens when liking and wanting get disconnected instead?

A global catalog shows how creatures across the tree of life balance rigidity with flexibility in remarkably consistent ways ...

Let's look at the pros and cons of going full AI to help you understand how the value and purpose of software development ...

This transcript was prepared by a transcription service. This version may not be in its final form and may be updated. Belle Lin: Welcome to Tech News Briefing. It's Tuesday, December 23rd. I'm Belle ...